Study S000292

A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07243171
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 126
Start: 2025-11-18
Primary completion: 2027-01-05
Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Conditions: Overweight and/or Obesity; Weight Management
Interventions: DRUG:ecnoglutide tablets; DRUG:placebo with matching dosage
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The incidence and severity of adverse events [up to day 204]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.